If left untreated, SDH expansion puts added pressure on the brain, which can lead to damage, impaired neurological function and even death. 

Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.

"Today’s sentence sends a deterrent message to doctors and the healthcare industry," according to a DOJ statement. "If you abuse patient trust for profit, you will face justice."

Placenta accreta spectrum is a serious and sometimes deadly perinatal complication. Instances of the condition have risen in recent decades, potentially due to an increase in cesarean deliveries.

Prem Soman, MD, PhD, explained how early detection and new therapies have been game-changers for the treatment and diagnosis of cardiac amyloidosis.

Summa Health said the change will take effect Sept. 1, with the two-hospital network ceasing scheduling of appointments for this consumer segment.

Its alert pertains to over 26K carotid artery stents, used by interventional neuroradiologists, vascular surgeons and other docs to prevent strokes. 

The Plantation, Florida, company first announced the initiative at RSNA 2024, offering clients new “relocatable and expandable” centers to be deployed across the U.S. 

The breast imaging group is launching two locations in Texas and marking its first foray into the Raleigh metro area, with more on the way in North Carolina. 

FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category.